SUBSCRIBE
SUBSCRIBE
News   FDA

GlaxoSmithKline Obtains Additional Approval For Anti-Influenza Drug RELENZA In Japan

February 20, 2006 | 
1 min read
Tokyo, Feb 20, 2006 (JCN) - GlaxoSmithKline (GSK) has obtained approval for additional indication for RELENZA (zanamivir), its proprietary agent for treating influenza A and B virus infections, from the Ministry of Health, Labor and Welfare.
FDA Approvals Asia
GlaxoSmithKline
MORE ON THIS TOPIC
Man walking on a long wavy path with flag at the end, persistence, determination and ultimate business success - 3D Render
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
 · 
3 min read
 · 
Heather McKenzie
Racing Cars at the finish line
Approvals
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug
March 2, 2026
 · 
2 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: BMS, GSK, Aldeyra and More
March 2, 2026
 · 
4 min read
 · 
Tristan Manalac
Borrow money from friend, debt and loan, incentive or bonus payment, credit or lending concept, businessman hand giving money banknote to friend's hand.
FDA
FDA To Offer Bonus Payments for Speedy Drug Reviewers
February 27, 2026
 · 
1 min read
 · 
Annalee Armstrong